The company’s technology team operates with autonomy, bypassing central approval processes to prioritize rapid iteration. This structure is best exemplified by the development of VisionIQ, an AI-enabled computer vision tool designed to automate drug receiving and audit reconciliation. The project originated after an engineer observed a pharmacy technician spending two hours daily manually cross-referencing vials and expiration dates. Within six months of that observation, the tool moved from a pitch in an open innovation forum to full production, ultimately reducing clinical audit time by 95%.
CEO Brian Ansay attributes this agility to a workspace that elevates curiosity over rigid hierarchies. By treating technology as a primary product rather than a support function, the firm allows developers to build tools that solve immediate pain points for independent oncology and retina clinics. CTO Ravi Seshadri emphasizes that the organization’s innovation stems from empowering staff closest to the problems to act on their findings. The Fast Company selection process evaluated companies based on internal programming, cultural investment, and the ability to foster employee-led invention across various sectors.
Comments (0)
No comments yet. Be the first!